TBX2 was also shown to confer cisplatin resistance in breast cancer cells by activating CHK2 to ensure the phosphorylation and stability of p53 which enhances its transcriptional activation of p21Cip1 [17]. The gene discussed is CDKN1A; the disease is breast carcinoma.